<DOC>
	<DOCNO>NCT01414504</DOCNO>
	<brief_summary>Recently , controversy emerge regard role 23vPPV infant due potential immunological hypo-responsiveness ( i.e . poor immune response repeat vaccination ) . Although previous experience 23vPPV child PNG demonstrate protective efficacy acute low respiratory tract infection , investigator feel matter urgency determine 23vPPV administration provide elevated antibody concentration 3 5 year age , ensure immunological safety 23vPPV infant . Following consent eligibility assessment , baseline blood sample nose swab take , 0.1ml dose 23vPPV administer follow blood sample nose swab collect 28 day later . The investigator also collect data incidence ALRI study participant medical record review .</brief_summary>
	<brief_title>Pneumococcal Conjugate Vaccine Followup</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>PNG Infants age 3 5 yr age participate previous PNG Neonatal PCV study receive PPV 9 12 month age , age sexmatched control live village urban area Informed parental/guardian consent Known HIV infection immunosuppressive condition treatment . Prior receipt 2 dos pneumococcal polysaccharide vaccine</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>pneumococcal ,</keyword>
	<keyword>pneumococcal polysaccharide vaccine ,</keyword>
	<keyword>challenge dose ,</keyword>
	<keyword>hyporesponsiveness ,</keyword>
	<keyword>Papua New Guinea</keyword>
</DOC>